The earnings call presented several positive developments, particularly in the Medical segment with strong growth and strategic partnerships. However, these were offset by declines in consolidated revenue and challenges in the Manufacturing segment, along with financial impacts from foreign exchange fluctuations. The sentiment is a balance between the positive medical advancements and the negative pressures from other business areas.
Company Guidance -
Q3 2025
During Materialise NV's Second Quarter 2025 Financial Results Conference Call, the company provided guidance reflecting the ongoing geopolitical volatility and macroeconomic uncertainty impacting the business climate. They revised their full-year 2025 revenue guidance from the previously communicated range of EUR 270 million to EUR 285 million, down to EUR 265 million to EUR 280 million. Despite this slight reduction in revenue outlook, the company reaffirmed their adjusted EBIT guidance, maintaining it between EUR 6 million and EUR 10 million for the fiscal year. This decision was underpinned by the company's confidence in their operational cost efficiencies and the solid fundamentals of their business. Additionally, Materialise reported a strong balance sheet with a net cash position of EUR 63 million at the end of the second quarter, an increase of EUR 2 million since the beginning of the year, indicating robust cash flow management amidst challenging market conditions.
Medical Segment Growth
Materialise Medical achieved high double-digit growth with revenue increasing by almost 17% this quarter, posting a quarterly revenue record. The segment's adjusted EBITDA margin increased to 32.7%.
Gross Profit Margin Improvement
Gross profit margin increased to 58.3% in the second quarter, up from 57% the previous year, reflecting production efficiencies and changes in revenue mix.
Pilot Collaboration with Johnson & Johnson
Materialise announced a pilot collaboration with Johnson & Johnson's Surgical business in EMEA to advance the adoption of its Mimics thoracic planner solution in the respiratory market.
Positive Free Cash Flow
Materialise generated a positive free cash flow, which led to a net cash position of EUR 63 million at the end of Q2, an increase of EUR 2 million versus the beginning of the year.
Materialise (MTLS) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MTLS Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 24, 2025
$6.18
$5.32
-13.92%
Apr 24, 2025
$4.63
$5.29
+14.25%
Feb 20, 2025
$9.22
$5.96
-35.36%
Oct 24, 2024
$5.09
$6.02
+18.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Materialise NV (MTLS) report earnings?
Materialise NV (MTLS) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).
What is Materialise NV (MTLS) earnings time?
Materialise NV (MTLS) earnings time is at Oct 23, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.